Clinical Trial Update: Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing trastuzumab deruxtecan versus standard of care in recurrent ovarian cancer after progression on PARP inhibitors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Yonsei University | Conditions: Ovarian Cancer, Ovarian Carcinoma, Recurrent | Phase 2 | Status: RECRUITING